The Pharma Data

MAY 5, 2022

Today, 30-60% of patients with GvHD do not respond to first-line steroid treatment, underscoring the need for new approaches to ensure long-term treatment goals are met,” said Dr. Robert Zeiser, University Hospital Freiburg, Department of Haematology, Oncology and Stem Cell Transplantation, Freiburg, Germany.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

The Pharma Data

MARCH 8, 2021

Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Since licensed by Ridgeback, all funds used for the development of EIDD-2801/MK-4482 have been provided by Wayne and Wendy Holman and Merck. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. Specifically, it is being examined in adults who are hospitalized with COVID-19. Kate Krav-Rude/Shutterstock. before expanding it into Europe.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

OCTOBER 6, 2021

It is also licensed under the brand name Efluelda ® in Europe where it is indicated for adults aged 60 and older. It is also licensed under the brand name Efluelda® in Europe where it is indicated for adults aged 60 and older. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 14, 2021

“Buprenorphine is the most important medication in our arsenal for treating opioid use disorder, which is currently one of the most lethal diseases for Americans.” As a result, some clinicians are hesitant to pursue this DEA license or even engage in treatment of patients with OUD.

Treatment 52

Treatment Licensing Licensing Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs. and Europe.

FDA 52

FDA Licensing Licensing Pharmaceuticals 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. This press release features multimedia. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

MARCH 4, 2021

Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Dupixent is approved in the U.S. Outside of the U.S., About Regeneron.

FDA 52

FDA Disease Treatment FDA Approval 52

The Pharma Data

SEPTEMBER 2, 2021

As a global leader in respiratory and allergy, we remain committed to reimagining medicine for patients living with chronic respiratory diseases like asthma.”. GLY certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura. g) and medium-dose (150/50/80?g)

Licensing 52

Licensing Licensing Treatment Therapies 52

The Pharma Data

OCTOBER 19, 2020

Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About PNEU-PATH.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

MARCH 2, 2021

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S.

Vaccine 52

Vaccine Clinical Trials FDA Licensing 52

The Pharma Data

APRIL 4, 2022

The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalised with COVID-19,” said Levi Garraway, M.D., today announced that the U.S. A decision on U.S. FDA approval is expected in the second half of this year.

Treatment 52

Treatment FDA Approval Clinical Trials FDA 52

The Pharma Data

NOVEMBER 5, 2020

“Data from the DISCOVER-1 and DISCOVER-2 studies demonstrating Tremfya reduced fatigue through 52 weeks provide evidence of an additional treatment benefit for patients with active PsA,” said Alyssa Johnsen, vice president, Rheumatology Disease Area Leader, Janssen Research & Development. Humanigen’s Lenzilumab. Equillium’s Itolizumab.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

MARCH 27, 2022

Food and Drug Administration (FDA) granted priority review for OLUMIANT in severe AA as a potential first-in-disease medicine. “Whether people with alopecia areata suffer loss of all the hair on their body or bald spots and missing eyebrows or eyelashes, this autoimmune disease can be devastating. In February 2022, the U.S.

Licensing 40

Licensing Licensing Disease FDA Approval 40

The Pharma Data

SEPTEMBER 8, 2020

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.

Treatment 52

Treatment Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 18, 2021

At the same time, we continue to prepare for the filing of the Biologics License Application with the U.S. million in 2020 despite a very limited access of patients to hospitals due to the COVID-19 crisis. “We Cash position and financing runway. million in the fourth quarter of 2020, and to a total of €5.6 GenSight Biologics S.A.

Treatment 40

Treatment Therapies Clinical Trials Marketing 40

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). The Phase 3 portion of this trial continues in non-hospitalized patients. In total, 47% of participants were male and 53% were female. .

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 9, 2020

1,2 Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. About Severe Asthma Asthma is a complex and heterogeneous disease affecting an estimated 339 million people worldwide. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 23, 2020

The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease. . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 29, 2020

. “Our foundation for the future is stronger than ever, and by maintaining our focus on serving patients and delivering for shareholders, I am confident that we will continue to build on our success to date and further advance our mission of delivering life-changing therapies to people with rare diseases and devastating conditions.”

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

The Pharma Data

NOVEMBER 9, 2020

We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. Albert Bourla, Pfizer Chairman and CEO. “We About BioNTech.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 1, 2020

will reduce the number of people in the high-risk population being hospitalized. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. “The Emergency Use Authorization in the U.K. About BioNTech.

Vaccine 40

Vaccine Clinical Trials Trials Production 40

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Published June 27, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Biocryst and Peter Marks, as well as updates from UCB and Altimmune that you may have missed. An oral solution of fenfluramine is already cleared in the U.S.

Vaccine 130

Vaccine FDA Therapies Licensing 130

The Pharma Data

JULY 2, 2025

Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) and granted it priority review status, seeking to update the U.S. The product was developed under a licensing agreement with Bristol Myers Squibb. If approved, the updated U.S. Source link

Trials 52

Trials FDA Licensing Licensing 52

Broad Institute

FEBRUARY 29, 2024

By Leah Eisenstadt February 29, 2024 Credit: Courtesy of (clockwise, from top left) National Park Service; Rainer Zenz, Creative Commons license; Len Charnoff/Flickr, public domain; Riki7, public domain; National Park Service; Rufus46, Creative Commons. The work appears in Proceedings of the National Academy of Sciences (PNAS).

Hospitals 116

Hospitals Medical Schools International Research 116

The Pharma Data

APRIL 8, 2021

. “While COV-BARRIER did not hit the primary endpoint based on stages of disease progression, the data show that baricitinib meaningfully reduced the risk of mortality above and beyond the recommended standard of care, without additional safety risks. and 14.7%, respectively) and placebo (44.4% and 18.0%, respectively) groups.

Hospitals 52

Hospitals FDA Approval Laboratories Treatment 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D., In the U.S.

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

APRIL 26, 2022

— Approval is Supported by Phase 2/3 Data Demonstrating the Safety and Tolerability Profile and Clinical Improvement Outcome in Hospitalized Pediatric Patients Treated with Veklury — Gilead Sciences, Inc. At this time, more than half of patients hospitalized with COVID-19 in the United States are treated with Veklury.

Treatment 52

Treatment Hospitals Science Licensing 52

The Pharma Data

NOVEMBER 20, 2020

Casirivimab and imdevimab are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19. . “The Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

Codon

FEBRUARY 13, 2024

alone, according to the Centers for Disease Control and Prevention. Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. 4 But the same barriers still exist today.

Therapies 137

Therapies Virus DNA Clinical Trials 137

Codon

FEBRUARY 27, 2024

Most square centimeters of our built environments transmit next to no disease (think of walls, which we rarely so much as brush in passing), but some are touched with extraordinary frequency. Diarrheal diseases—attributed to viruses, such as noroviruses, which are spread via fomite transmission—killed about 1.5

Virus 74

Virus Hospitals Production Regulations 74

The Pharma Data

AUGUST 3, 2021

While disease progression is slower in patients with later-onset SMA, there are significant unmet needs. “We SMA is a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, resulting in the irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement.

Clinical Trials 52

Clinical Trials Trials Therapies Licensing 52